Order Article Reprints

Marco DN, Molina M, Guio A-M, Julian J, Fortuna V, Fabregat-Zaragoza V-L, Salas M-Q, Monge-Escartín I, Riu-Viladoms G, Carcelero E, et al. Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation. Pharmaceuticals. 2024; 17(5):553. https://doi.org/10.3390/ph17050553

Marco, Daniel N., Mònica Molina, Ana-María Guio, Judit Julian, Virginia Fortuna, Virginia-Lucila Fabregat-Zaragoza, María-Queralt Salas, Inés Monge-Escartín, Gisela Riu-Viladoms, Esther Carcelero, and et al. 2024. "Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation" Pharmaceuticals 17, no. 5: 553. https://doi.org/10.3390/ph17050553

Marco, D. N., Molina, M., Guio, A.-M., Julian, J., Fortuna, V., Fabregat-Zaragoza, V.-L., Salas, M.-Q., Monge-Escartín, I., Riu-Viladoms, G., Carcelero, E., Roma, J. R., Llobet, N., Arcarons, J., Suárez-Lledó, M., Rosiñol, L., Fernández-Avilés, F., Rovira, M., Brunet, M., & Martínez, C. (2024). Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation. Pharmaceuticals, 17(5), 553. https://doi.org/10.3390/ph17050553